Integra LifeSciences (IART) Bank of America Global Healthcare Conference 2026 summary

Leadership transition and strategic focus

• CEO transition to Stuart as Chairman and CEO, with continued focus on transformation and operational capability improvements.

• Emphasis on accelerating commercial strategy and growth, especially in neurosurgery, tissue reconstruction, and ENT, targeting a $9 billion addressable market.

• No change in core business focus; company remains a leader in niche markets with durable demand.

Operational improvements and growth drivers

• Q1 results exceeded revenue and EPS guidance, reflecting transformation progress.

• Reduced supply disruptions, improved supply chain visibility, and yield enhancements support consistent demand fulfillment.

• Regulatory audit outcomes and improved cash flow signal lower business volatility and sustainable performance.

Commercial strategy and product launches

• No near-term expansion of sales force; focus on optimizing existing team and leveraging strong customer relationships.

• Growth to be driven by bringing off-market products back, portfolio expansion, and adapting to reimbursement changes.

• Analytical tools to enhance commercial efficiency without increasing sales force size.